scispace - formally typeset
Open AccessJournal ArticleDOI

Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.

Reads0
Chats0
TLDR
The findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments.
Abstract
Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those with dilated forms of cardiomyopathy. The gross pathologic changes of increased LV volume and perturbation in the normal elliptical LV chamber configuration is driven, on a histologic level, by myocyte hypertrophy and apoptosis and by increased interstitial collagen. Each of the techniques used for tracking this process—echocardiography, radionuclide ventriculography, and cardiac magnetic resonance—carries advantages and disadvantages. Numerous investigations have demonstrated the value of LV volume measurement at a single time-point and over time in predicting clinical outcomes in patients with heart failure and in those after myocardial infarction. The structural pattern of LV remodeling and evidence of scarring on cardiac magnetic resonance have additional prognostic value. Beyond the impact of abnormal cardiac structure on cardiovascular events, the relationship between LV remodeling and clinical outcomes is likely linked through common local and systemic factors driving vascular as well as myocardial pathology. As demonstrated by a recent meta-analysis of heart failure trials, LV volume stands out among surrogate markers as strongly correlating with the impact of a particular drug or device therapy on patient survival. These findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments.

read more

Citations
More filters
Journal ArticleDOI

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.

TL;DR: This exploratory study of patients with heart failure and reduced ejection fraction treated with sacubitril-valsartan found a correlation between changes in log2-NT-proBNP concentrations and left ventricular (LV) EF,LV end-diastolic volume index (LVEDVI), LV end-systolic volumeIndex (LVESVI), left atrial volume index(LAVI), and ratio of early transmitral Doppler velocity/early diastolic
OtherDOI

Pathophysiology of Heart Failure.

TL;DR: This summary of the pathophysiology of heart failure tries to give a compact overview of basic mechanisms and of the novel unfolding, progressive theory ofHeart failure to contribute to a more comprehensive knowledge of the disease.
References
More filters
Journal ArticleDOI

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI

The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.

TL;DR: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization and is strongly related to the degree of improvement in the global mean wall-motion score and the ejection fraction after Revascularization.
Related Papers (5)